F10 and Stroke: There were significant differences between the patient population studied in the XAPASS and the patient population enrolled in the Japanese phase 3 clinical trial Japanese Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (J-ROCKET AF; NCT00494871) [9, 10].